GEORGETOWN, Texas -- (BUSINESS WIRE) -- Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapies announced today that it presented preclinical data in two poster presentations at the 105th annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA from April 5th – 9th, 2014. In a presentation, entitled “CD20-specific Engineered Toxin Body Demonstrates Direct Cell Kill Of Multiple B-cell Non-Hodgkin‘s Lymphoma Types” (Abstract 647), the company reported on the development of MT-3724 that specifically targets the destruction of malignant cells expressing the CD20 receptor through a unique mechanism of cell kill. In a separate poster presentation entitled “CD38-specific Engineered Toxin Body: Therapeutic potential for multiple myeloma” (Abstract 671), the company presented preclinical data highlighting the potent and specific anti-CD38 effects of a lead compound in development for the treatment of multiple myeloma.
“We are excited to present preclinical data that demonstrate the unique capabilities of our platform technology and these two maturing lead programs,” said Eric Poma, CEO and CSO, Molecular Templates. “Our technology represents a new class of targeted therapies with distinct advantages over traditional ADC. Our lead compound, MT-3724, will enter clinical studies this year for lymphoma and our CD38 program is advancing toward the clinic as well.”
About Molecular Templates
Molecular Templates is a biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapeutics called Engineered Toxin Bodies (ETBs). The company is pursuing development of various leads across a wide range of cancers.
For more information, please visit www.moleculartemplates.com.